Introduction
Materials and methods
Adoptive activated T lymphocyte immunotherapy
Case enrollment
Data on patient characteristics
Patient characteristics | Total | BSC | IT | CT | ICT | CRT | ICRT |
---|---|---|---|---|---|---|---|
n = 540 |
n = 25 |
n = 31 |
n = 207 |
n = 132 |
n = 118 |
n = 27 | |
Age (years old) | |||||||
Median | 65 | 77 | 71 | 65 | 60 | 69 | 60 |
Range (25, 75%) | (58, 73) | (70, 83) | (59, 78) | (59, 73) | (54, 67) | (61, 74) | (51, 67) |
Gender | |||||||
M:F | 366:174 | 17:08 | 21:10 | 134:73 | 79:53 | 97:21 | 18:09 |
(%) | 67.8:32.2 | 68:32 | 67.8:32.2 | 64.7:35.2 | 59.8:40.2 | 82.2:17.8 | 66.7:33.3 |
Stage | |||||||
III:IV | 166:374 | 8:17 | 8:23 | 47:160 | 21:111 | 65:53 | 17:10 |
(%) | 30.7:69.3 | 32:68 | 25.8:74.2 | 22.7:77.3 | 15.9:84.1 | 55.1:44.9 | 63.0:37.0 |
Histology | |||||||
Aden:squa | 374:126 | 13:11 | 20:6 | 148:43 | 111:12 | 63:47 | 19:7 |
(%) | 74.8:25.2 | 54.2:45.8 | 76.9:23.1 | 77.5:22.5 | 90.2:9.8 | 57.3:42.7 | 73.1:26.9 |
PS | |||||||
0:1 | 322:218 | 15:10 | 16:15 | 131:76 | 63:69 | 78:40 | 19:8 |
(%) | 59.6:40.4 | 60:40 | 51.6:48.4 | 63.3:36.7 | 47.7:52.3 | 66.1:33.9 | 70.4:29.6 |
Organ metastases | |||||||
Pleura (%) | 0 | 47.4 | 6.3 | 23.3 | 0 | 13.6 | |
Lung (%) | 23.1 | 42.1 | 38.0 | 31.4 | 24.6 | 13.6 | |
Brain (%) | 38.5 | 21.1 | 27.5 | 29.1 | 42.1 | 45.5 | |
Bone (%) | 76.9 | 10.5 | 43.0 | 34.9 | 24.6 | 36.4 | |
Liver (%) | 23.1 | 5.3 | 14.1 | 9.3 | 8.8 | 0 | |
Adrenal glands (%) | 0 | 0 | 7.7 | 7.0 | 14.0 | 4.5 | |
Others (%) | 15.4 | 21.1 | 8.5 | 19.8 | 12.3 | 31.8 | |
Mean no. of metastasis sites/patient | 1.46 | 1.47 | 1.45 | 1.55 | 1.26 | 1.45 | |
Treatment | |||||||
Platinum + %a
| 84.8 | 0 | 0 | 86.5 | 86.3 | 88.1 | 88.9 |
Gefinitib + %b
| 31.0 | 0 | 0 | 34.7 | 41.6 | 18.6 | 7.4 |
No. of IT infusions | |||||||
Median | 8.7 | – | 8.0 | – | 6.0 | – | 7.0 |
Range (25, 75%) | (6.0, 10.0) | – | (6.0, 15.0) | – | (4.5, 10.0) | – | (6.0, 11.0) |
Follow-up (mo.) | |||||||
Median | 15.2 | 4.0 | 15.2 | 13.2 | 17.3 | 16.3 | 18.3 |
Range (25, 75%) | (8.1, 26.9) | (3.0, 6.0) | (7.6, 28.4) | (7.1, 26.4) | (11.2, 27.4) | (9.1, 29.4) | (13.2, 38.6) |
Survival time calculation
End point of the study
Statistic analysis
Studies on performance status (PS) of the patients underwent immunotherapy
Results
Variate | Hazard ratio | 95% CI, (upper and lower) |
p value | |
---|---|---|---|---|
Gender | ||||
Male | 1 | |||
Female | 0.68 | 0.59 | 0.78 | <0.0001 |
Age | ||||
≥70 | 1 | |||
<70 | 0.87 | 0.77 | 0.99 | 0.384 |
Histology | ||||
Squamous | 1 | |||
Adeno carcinoma | 0.89 | 0.77 | 1.02 | 0.1015 |
Stage | ||||
IV | 1 | |||
III | 0.83 | 0.72 | 0.95 | 0.006 |
PS | ||||
0 | ||||
1 | 1.05 | 0.93 | 1.18 | 0.3976 |
Chemotherapy | ||||
No | 1 | |||
Yes | 0.69 | 0.57 | 0.85 | 0.0009 |
Radiotherapy | ||||
No | 1 | |||
Yes | 0.81 | 0.69 | 0.93 | 0.003 |
Immunotherapy | ||||
No | 1 | |||
Yes | 0.81 | 0.93 | 1.18 | 0.0016 |
Group | Treatment | Hazard ratio | 95% CI |
p value |
---|---|---|---|---|
Male/squamous | IT | 0.75 | 0.51, 1.04 | 0.088 |
CT | 0.75 | 0.52, 1.13 | 0.16 | |
RT | 0.71 | 0.55, 0.92 | 0.009 | |
Male/adenocarcinoma | IT | 0.386 | 0.32, 1.03 | 0.102 |
CT | 0.63 | 0.48, 0.85 | 0.003 | |
RT | 0.79 | 0.63, 0.98 | 0.032 | |
Female/adeno. | IT | 0.73 | 0.55, 0.94 | 0.016 |
CT | 0.76 | 0.48, 1.40 | 0.339 |
Subgroup | Hazard ratio | IT on CT 95% CI |
p value | Hazard ratio | RT on CT 95% CI |
p value |
---|---|---|---|---|---|---|
Male/squamous | 0.915 | 0.618, 1.276 | 0.621 | 0.67 | 0.508, 0.878 | 0.004 |
Male/adenocarcinoma | 0.869 | 0.721, 1.041 | 0.128 | 0.736 | 0.596, 0.899 | 0.002 |
Female/squamous | 0.818 | 0.374, 1.604 | 0.567 | nd | nd | nd |
Female/adenocarcinoma | 0.758 | 0.572, 0.985 | 0.038 | nd | nd | nd |